Stem cell therapy for ALS (amyotrophic lateral sclerosis) in Republic of Korea — get 3 top clinic matches with costs

Neuronata-R remains available for ALS treatment in South Korea under conditional approval. The Ministry of Food and Drug Safety (MFDS) maintained this status after Phase 3 trial reviews showed benefits for slow-progressing patients. Corestemchemon has resumed manufacturing to ensure access.

• Regulatory status: Ministry of Food and Drug Safety maintains conditional approval despite trial results.
• Clinical findings: Data shows improved survival and function for slow-progressing ALS patient subgroups.
• Labeling update: New clinical data from the ALSummit trial now informs product labeling.
• Global access: Manufacturer plans to seek United States regulatory guidance for future availability.

Bookimed Expert Insight: Patient data shows South Korea remains a key hub with 96 clinics. RE:YOUTH Clinic even offers arterial infusion to only 2 patients daily. This focus on small patient groups helps maintain safety during specialized stem cell protocols.

Patient Consensus: Patients emphasize that this treatment slows decline rather than curing the disease. They warn that starting this therapy may disqualify you from other clinical trials later.

South Korea approved Neuronata-R for amyotrophic lateral sclerosis treatment. This autologous bone marrow-derived mesenchymal stem cell therapy received conditional approval from the Ministry of Food and Drug Safety. Doctors use intrathecal injections to slow functional decline in patients with this neurodegenerative condition.

• Therapy developer: CorestemChemon produced this bone marrow-derived mesenchymal stem cell product.
• Regulatory status: Ministry of Food and Drug Safety granted conditional orphan drug approval.
• Administration method: Specialists deliver the treatment via intrathecal injection into the spinal canal.
• Clinical purpose: The protocol aims to slow disease progression rather than restoring lost function.

Bookimed Expert Insight: While Neuronata-R is the standard regulated choice, specialized centers like RE:YOUTH offer alternative delivery methods. They use direct arterial infusion instead of spinal injections. This clinic serves 1,000 patients yearly but limits daily intake to 2 people for focused care.

Patient Consensus: Patients emphasize distinguishing between the regulated Neuronata-R product and non-regulated private protocols. Many recommend consulting an ALS neurologist to verify if a clinic offers registered trials or private treatments.

Neuronata-R treats ALS in South Korea by using autologous mesenchymal stem cells to slow functional decline. The therapy uses immunomodulation and neuroprotection to shield motor neurons from damage. It holds conditional approval from the Ministry of Food and Drug Safety for patients in the Republic of Korea.

• Cell harvesting: Surgeons extract bone marrow from the patient to minimize immune rejection risks.
• Laboratory expansion: Specialists multiply specific stem cells in a lab to reach therapeutic concentrations.
• Intrathecal injection: Doctors deliver cells mixed with cerebrospinal fluid directly into the spinal canal.
• Neuroprotective action: Secreted molecules like brain-derived neurotrophic factor support surviving motor neurons.
• Inflammation control: The treatment helps lower damaging proteins like TNF-alpha while boosting anti-inflammatory cells.

Bookimed Expert Insight: South Korea is a global hub for regenerative medicine, ranking 2nd in our global market data. While Neuronata-R is standard, clinics like RE:YOUTH now offer direct arterial infusion. This specialized approach aims to improve cell delivery but limits intake to 2 daily patients for safety.

Patient Consensus: Patients emphasize that this therapy aims to slow disease progression rather than restore lost functions. Many advise consulting an independent neurologist to balance these treatments with standard multidisciplinary care like riluzole.

Patients with a confirmed amyotrophic lateral sclerosis diagnosis may receive stem cell therapy in South Korea. Candidates must typically use the treatment as an add-on to riluzole and have sufficient health for bone marrow aspiration. Specialists prioritize patients with specific progression rates and stable respiratory function.

• Medical diagnosis: Patients must have confirmed sporadic or familial amyotrophic lateral sclerosis.
• Current medication: Candidates usually take riluzole unless they have severe medical contraindications.
• Physical fitness: Patients must be healthy enough for bone marrow harvesting and spinal injections.
• Progression rate: Neurologists often favor patients showing slower or intermediate functional decline.
• Treatment window: Protocol eligibility may depend on the time passed since the first symptoms.

Bookimed Expert Insight: Clinics like RE:YOUTH draw on arterial infusion methods rather than standard spinal injections. This clinic limits intake to 2 daily patients to focus on safety. Patients should check if their clinic uses regulator-approved products or experimental protocols before booking.

Patient Consensus: Patients emphasize that eligibility depends on strict clinical protocols and disease stages. It is vital to request written criteria regarding respiratory function and ALSFRS-R scores before traveling.

International patients can travel to South Korea for Neuronata-R treatment, but access requires approval from local neurologists and a Ministry of Food and Drug Safety evaluation. This autologous bone marrow-derived therapy is available at specialized centers in Seoul and Cheonan for eligible ALS cases.

• Approval status: South Korea holds conditional license for Neuronata-R after Phase 3 trials.
• Logistical requirement: Process involves bone marrow extraction, lab culture, and intrathecal injection cycles.
• Evaluation process: Patients must undergo in-person clinical exams to confirm disease progression rates.
• Treatment cost: Procedures range from $15,000 to $30,000 for international patients.

Bookimed Expert Insight: While Neuronata-R is the most recognized brand, clinics like RE:YOUTH (YONSEI BH) offer alternative arterial stem cell infusions. This approach serves about 1,000 patients yearly. Patients should compare these direct arterial methods with the standard intrathecal injections used for Neuronata-R.

Patient Consensus: Results vary, with some noting slower progression while others see no change. Experts warn that these commercial treatments might disqualify you from future clinical trials elsewhere.